Creso Pharma Inc.
ASX: CPH, OTC: COPHF
Company Overview
The company announced its intent to acquire Halucenex Life Science in early 2021, which is a life science development company focused on researching novel psychedelic compounds, developing and licensing psychedelic compounds for the pharmaceutical and nutraceutical markets, and conducting clinical trials on the medical benefits of psychedelic medicine.
Halucenex operates a 6,000 sq. ft. medical facility in Windsor, Nova Scotia with six treatment rooms and a secure laboratory designed to perform psychedelic-assisted psychotherapy and clinical research.
Financial Highlights
$7,528,868
Revenue (ttm)
-$400,390
Gross Profit (ttm)
-$0.02
Diluted EPS (ttm)
Management Team
Mr. Boaz Wachtel M.A., M.D., MBA
Co-Founder & Non-Exec. Director
Mr. Christopher Grundy
Chief Financial Officer
Mr. William Lay B.Com.
Group CEO, MD & Director
Dr. Gian Trepp
Commercial & Marketing Director
Ms. Micheline MacKay B.Sc., M.Sc., P.M.P.
MD & Exec. Director
Ms. Jodi Scott
Exec. Director & Pres of US Operations
Ms. Erlyn Saromines Dawson A.C.I.S., ACIS, AGIA, B.Com., BCom., GradDipACG
Joint Company Sec.
Mr. Winton William Willesee C.P.A., GAICD, MAICD, MCom
Joint Company Sec.
Dr. Simon H. W. Buckingham
Consultant
Hon. Brian Walker
Strategic Consultant & Chair of Scientific Advisory Committee
Key Highlights
Market Capitalization
$0
Shares Outstanding
0
Shares Short (% of Float)
()
Insider Ownership
29%